title: [Efficacy of adalimumab in Behçet's disease. Description of 6 cases].
abstract: Behçet's disease (BD) is a systemic vasculitis, with a more aggressive course in young males. Orogenital ulcers, uveitis and cutaneous lesions are the most frequent manifestations. We analyzed the effects of adalimumab on six patients with BD pretreated with inmunosupressive therapy, two of whom had received infliximab. We observed a good clinical response in all patients. To date, after a mean follow-up of 26.8 months, patients continue receiving adalimumab, with good clinical control, no adverse effects have been reported with adalimumab.
authors.affiliation: Servicio de Reumatología y Metabolismo Óseo, Consorcio Hospital General Universitario, Valencia, España. calvo jav@gva.es
authors.forename: Javier
authors.initials: J
authors.lastname: Calvo Catalá
authors.forename: Cristina
authors.initials: C
authors.lastname: Campos Fernández
authors.forename: Amalia
authors.initials: A
authors.lastname: Rueda Cid
authors.forename: María Isabel
authors.initials: MI
authors.lastname: González-Cruz Cervellera
authors.forename: Aurelio
authors.initials: A
authors.lastname: Baixauli Rubio
authors.forename: María Dolores
authors.initials: MD
authors.lastname: Pastor Cubillo
mesh_terms: D000068879:Adalimumab; D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001528:Behcet Syndrome / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab